Observational analysis describes challenges managing ocular complications in patients with SJS and autoimmune diseases, suggesting systemic therapy may prevent progression.
Purpose To describe the clinical course and management challenges of chronic ocular complications in Stevens-Johnson syndrome (SJS) patients with co-existing autoimmune diseases, emphasizing the role of systemic immunomodulatory therapy (IMT) in controlling inflammation and preventing disease progression.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: